Biotechnology, electronics and life science company MOBILion Systems, Inc. announced on Wednesday a collaboration with Dr Oliver Schmitz from the University of Duisburg-Essen, a specialist in analytical chemistry for complex sample analysis.
This partnership highlights MOBILion's commitment to advancing multiomics research through its proprietary SLIM (Structures for Lossless Ion Manipulation) technology.
Dr Schmitz will integrate MOBILion's latest low mass system into his work on complex sample analysis, including Chinese herbal medicine and multidimensional chromatography workflows. The system addresses limitations of traditional LC-MS and ion mobility technologies, enabling precise and efficient metabolomics discovery. Cleaner, more focused data is achieved by reducing overlapping signals, simplifying molecular identification and interpretation.
MOBILion continues to expand its SLIM-based product pipeline, supporting breakthroughs in proteomics, lipidomics, glycomics, and metabolomics. This collaboration builds on the company's recent progress in proteomics applications and commercial platform development.
Genflow Biosciences receives first EUR336,467 tranche of EUR4m Wallonia grant
Novacyt completes acquisition of Southern Cross Diagnostics
Atrium Therapeutics launches as newly independent, publicly traded company
Innovent Biologics' Jaypirca approved in China for new indication
Gemma Biotherapeutics doses first parent in GB221 Phase 1/2 CHARISMA clinical trial
Neurizon Therapeutics doses first participant in NUZ-001 Regimen I HEALEY ALS Platform Trial
Melodia Therapeutics reports award of US patent covering MLD-151
Argo Biopharmaceutical to present BW-20805 Phase II interim data at AAAAI 2026 Annual Meeting